Year Founded
2021
Ownership
Private
Employees
~50
Stage
Preclinical
Modalities
Small moleculePeptidesProteolysis-targeting chimera (PROTAC)Other

RECEPTOR.AI General Information

Company has developed an AI-powered drug discovery platform with 40+ projects and 86% success rate. Currently has 4 internal programs in early discovery/preclinical stages targeting nephrology, oncology, inflammation and cardiology indications.

Contact Information

Website
Primary Industry
TechBio
Corporate Office
London,
United Kingdom

Drug Pipeline

RAI-001
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to RECEPTOR.AI's pipeline data

Book a demo

Key Partnerships

Moexa Pharmaceuticals, Nvidia, Unnamed major pharmaceutical company

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

RECEPTOR.AI Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view RECEPTOR.AI's complete valuation and funding history, request access »